23 Jul, 2018

Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801

alzheon2024-08-05T15:03:03-04:00July 23rd, 2018|

Read More

22 May, 2018

Alzheon to Make Presentations at Upcoming Industry and Investor Conferences

alzheon2024-08-05T18:11:36-04:00May 22nd, 2018|

Read More

2 Nov, 2017

Alzheon ALZ-801 Data Presented in Oral Session at CTAD on Role of Amyloid Oligomers in Alzheimer’s Disease

alzheon2024-08-05T17:37:42-04:00November 2nd, 2017|

Read More

2 Nov, 2017

Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease Over 130 Weeks: Results of Phase 3 Extension Study

alzheon2019-09-23T12:10:48-04:00November 2nd, 2017|

Read More

24 Oct, 2017

FDA Grants Fast Track Designation to Alzheon’s ALZ-801 Development Program for the Treatment of Alzheimer’s Disease

alzheon2024-08-05T17:32:43-04:00October 24th, 2017|

Read More

24 Oct, 2017

Alzheon Publishes Clinical Results that Demonstrate Safety Profile and Efficacy Potential of ALZ-801 as an Orally-Available Precision Medicine to Treat Alzheimer’s Disease

alzheon2024-08-05T19:12:51-04:00October 24th, 2017|

Read More

23 Oct, 2017

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

alzheon2019-09-23T12:10:48-04:00October 23rd, 2017|

Read More

12 Oct, 2017

Alzheon to Make Presentations on ALZ-801 and its Anti-Oligomer Mechanism at the 10th Clinical Trials on Alzheimer’s Disease Congress

alzheon2024-08-02T13:22:41-04:00October 12th, 2017|

Read More

20 Sep, 2017

Alzheon to Make Keynote and Featured Presentations at Upcoming Scientific and Industry Conferences

alzheon2024-08-05T18:29:09-04:00September 20th, 2017|

Read More

17 Jul, 2017

Alzheon updates on precision medicine approach to treating AD

alzheon2019-09-23T12:10:48-04:00July 17th, 2017|Tags: thepharmaletter|

Read More